Summary THJ-2201 is a synthetic cannabinoid based on the indazole structure, and it is believed to function as a potent agonist for the CB1 receptor. This compound has been available for purchase online as a designer drug. Structurally, THJ-2201 is…
Summary SDB-005 is a synthetic cannabinoid based on the indazole structure and has been made available for purchase online as a designer drug. It is believed to act as an agonist for the CB1 and CB2 cannabinoid receptors. Notably, SDB-005…
Summary PX-3, or APP-CHMINACA, is a synthetic cannabinoid rooted in the indazole structure. Developed by Pfizer in 2009, its original purpose was as an analgesic medication, showcasing potential pharmaceutical utility.This compound’s acronym, ‘APP,’ signifies its structural elements: ‘amino,’ ‘phenyl,’ and…
Summary PX-2, also recognized as 5F-APP-PINACA, FU-PX, and PPA(N)-2201, represents an indazole-based synthetic cannabinoid that has been available for online purchase under the designation of a designer drug. This compound incorporates a phenylalanine amino acid amide within its structural composition.…
Summary MN-18, an indazole-based synthetic cannabinoid, acts as an agonist for cannabinoid receptors, featuring Ki values of 45.72 nM at CB1 and 11.098 nM at CB2, alongside EC50 values of 2.028 nM at CB1 and 1.233 nM at CB2, highlighting…
Summary MDMB-FUBINACA, also referred to as MDMB(N)-Bz-F and FUB-MDMB, stands as an indazole-derived synthetic cannabinoid renowned for its remarkable potency in binding to cannabinoid receptors. It exhibits Ki values of 1.14 nM at CB1 and 0.1228 nM at CB2, with…
Summary MDMB-CHMINACA, also recognized as MDMB(N)-CHM, is an indazole-derived synthetic cannabinoid renowned for its robust affinity as a CB1 receptor agonist. This compound has gained notoriety as an online designer drug. Originally developed by Pfizer in 2008, MDMB-CHMINACA is among…
Summary MDMB-4en-PINACA, often erroneously referred to as 5-CL-ADB-A, is an indazole-based synthetic cannabinoid that has gained popularity as an online designer drug. In 2021, the Drug Enforcement Administration (DEA) in the United States reported MDMB-4en-PINACA as the most prevalent synthetic…
Summary FAB-144, classified as an indazole-derived synthetic cannabinoid, is believed to exhibit vigorous agonistic activity towards the CB1 receptor. This compound has gained notoriety for its online availability as a designer drug and is the indazole counterpart of XLR-11. Identifiers…
Summary CUMYL-THPINACA also recognized as SGT-42, is categorized as an indazole-3-carboxamide-based synthetic cannabinoid. This compound is a robust agonist for cannabinoid receptors, exhibiting approximately 6 times greater selectivity for CB1. Specifically, it boasts an EC50 of 0.1nM for human CB1…
